anastrozole and Orthopedic Disorders studies

Research Excerpts

Excerpt	Relevance	Reference
"Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms."	6.71	Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004)
"The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - positive breast cancer in postmenopausal women."	4.84	The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. ( Fabian, CJ, 2007)
"We conducted a prospective study including postmenopausal early breast cancer patients receiving either an aromatase inhibitor (AI) or tamoxifen."	3.77	Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. ( Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H, 2011)
"Patients with early breast cancer and AIMSS were stratified according to their baseline 25-hydroxy vitamin D (25OHD) level."	2.76	Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. ( Armamento-Villareal, R; Ellis, MJ; Gao, F; Jamalabadi-Majidi, S; Napoli, N; Rastelli, AL; Taylor, ME, 2011)
"Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms."	2.71	Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004)

Research

Studies (8)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Average Percent Adherence to Vitamin D Interventio

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (37.50)	29.6817
2010's	5 (62.50)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Shapiro, AC	1
Adlis, SA	1
Robien, K	1
Kirstein, MN	1
Liang, S	1
Richter, SA	1
Lerner, RE	1
Briot, K	1
Tubiana-Hulin, M	1
Bastit, L	1
Kloos, I	1
Roux, C	1
Ingle, JN	1
Lintermans, A	1
Van Calster, B	1
Van Hoydonck, M	1
Pans, S	1
Verhaeghe, J	1
Westhovens, R	1
Henry, NL	1
Wildiers, H	1
Paridaens, R	2
Dieudonné, AS	1
Leunen, K	1
Morales, L	2
Verschueren, K	1
Timmerman, D	2
De Smet, L	1
Vergote, I	2
Christiaens, MR	2
Neven, P	2
Rastelli, AL	1
Taylor, ME	1
Gao, F	1
Armamento-Villareal, R	1
Jamalabadi-Majidi, S	1
Napoli, N	1
Ellis, MJ	1
Van Limbergen, E	1
Carbonez, A	1
Van Huffel, S	1
Ameye, L	1
Winters, L	1
Habin, K	1
Gallagher, J	1
Fabian, CJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase 2 Study Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors[NCT01509079]	Phase 2	116 participants (Actual)	Interventional	2012-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

adherence measured with pill counts for the vitamin D at predesignated study timepoints: baseline (after run-in), 3 months and 6 months (NCT01509079)
Timeframe: average for all study ppts for: screening to baseline; baseline to 3 months; 3 month to 6 months

Change in Hand Grip Strength

Change in Musculoskeletal Symptom Sub-scale on the Breast Cancer Prevention Trial Symptom Scale

Intervention	% of adherence for each treatment arm (Number)
Vitamin D3 4000 IU	95
Vitamin D3 600 IU	95

Intervention	pounds (Mean)
Vitamin D3 4000 IU	1.8
Vitamin D3 600 IU	1.0

The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia (NCT01509079)
Timeframe: baseline to 6 months

Change in PROMIS Physical Functioning Questionnaire

Intervention	units on a scale (Mean)
Vitamin D3 4000 IU	-0.2
Vitamin D3 600 IU	-0.5

PROMIS measures physical functioning on the short form and higher scores reflect better physical functioning with 10 questions on daily activities of life on a Likert scale ranging from 5 (no problem performing activity) to 1 (cannot do activity). Range on this measure is from 50 (best)-10 (worst). (NCT01509079)
Timeframe: baseline to 6 months

Whole Body Bone Mineral Density

Intervention	units on a scale (Mean)
Vitamin D3 4000 IU	0.6
Vitamin D3 600 IU	1.7

GLM Mean and standard deviation of Whole Body Bone Mineral Density (grams/cm2) of Trial Participants by Treatment Arm after controlling for bisphosphonate use (NCT01509079)
Timeframe: From Baseline and 6 months of D3 supplementation

Change in Steady State Concentrations of Serum Anastrazole and Letrozole

Intervention	gm/cm2 (Geometric Least Squares Mean)
Vitamin D3 4000 IU	1.1
Vitamin D3 600 IU	1.12

Difference in steady state concentrations in plasma from baseline to 6 months (NCT01509079)
Timeframe: baseline to 6 months

Article	Year
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer. Clinical journal of oncology nursing, 2007, Volume: 11, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical	2007
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. International journal of clinical practice, 2007, Volume: 61, Issue:12 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemot	2007

Article	Year
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast cancer research and treatment, 2016, Volume: 155, Issue:3 Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Bone De	2016
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast cancer research and treatment, 2010, Volume: 120, Issue:1 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans	2010
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations. Breast cancer research : BCR, 2010, Dec-20, Volume: 12 Suppl 4 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Con	2010
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast cancer research and treatment, 2011, Volume: 129, Issue:1 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density	2011
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anti-cancer drugs, 2004, Volume: 15, Issue:8 Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation,	2004

anastrozole and Orthopedic Disorders